Cend Therapeutics Announces Publication of Pancreatic Cancer Trial Data in the Lancet Gastroenterology and Hepatology
06 juil. 2022 08h05 HE
|
Cend Therapeutics Inc.
SAN DIEGO, July 06, 2022 (GLOBE NEWSWIRE) -- Cend Therapeutics, Inc. (“Cend”), a privately-held, clinical-stage drug discovery and development company developing a novel approach to enable more...
Cend Therapeutics Announces First Patient Treated in Phase 2b Trial of CEND-1 led by Australasian Gastro-Intestinal Trials Group
09 juin 2022 08h05 HE
|
Cend Therapeutics Inc.
SAN DIEGO, June 09, 2022 (GLOBE NEWSWIRE) -- Cend Therapeutics, Inc. (“Cend”) today announced that the first patient has been treated in the Phase 2b study of CEND-1, Cend’s lead investigational...
Caladrius Biosciences and Cend Therapeutics Announce Definitive Merger Agreement
27 avr. 2022 08h00 HE
|
Cend Therapeutics Inc.
Combined company to be renamed Lisata Therapeutics upon transaction closing Combination will create a financially sound Nasdaq-listed company with a diverse product development pipeline, strong...
Cend Therapeutics Announces First Patient Dosing in Clinical Trial of CEND-1 for the Treatment of Selected Gastrointestinal Cancers
16 nov. 2021 06h00 HE
|
Cend Therapeutics Inc.
SAN DIEGO, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Patient dosing has begun in a Phase 1b/2a clinical trial to evaluate the safety, tolerability and pharmacologic activity of CEND-1 in pancreatic,...
Cend Therapeutics’ CEND-1 Granted Fast Track Designation for Pancreatic Cancer
29 juin 2021 08h00 HE
|
Cend Therapeutics Inc.
SAN DIEGO, June 29, 2021 (GLOBE NEWSWIRE) -- The US Food and Drug Administration (FDA) has granted Fast Track Development (FTD) status for Cend’s investigational drug, CEND-1, for the first-line...
Cend Therapeutics and Qilu Pharmaceutical Announce Partnership
16 févr. 2021 08h00 HE
|
Cend Therapeutics Inc.
SAN DIEGO and JINAN, China, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Cend Therapeutics, Inc., a clinical-stage biotech company, and Qilu Pharmaceutical, a major Chinese pharmaceutical company, announced...
Cend Therapeutics Announces Acquisition of Impilo Therapeutics
21 sept. 2020 07h00 HE
|
Cend Therapeutics Inc.
SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Cend Therapeutics, Inc., a clinical-stage biotech company, announced today that it has acquired Impilo Therapeutics, Inc. The combination expands Cend’s...
Cend Therapeutics Announces Presentation and Abstract Publication at 2020 European Society for Medical Oncology (ESMO) Meeting
15 sept. 2020 07h00 HE
|
Cend Therapeutics Inc.
SAN DIEGO, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Cend Therapeutics, Inc., a clinical-stage biotech company, announced the publication of its abstract on the website of the annual meeting of the...
CEND Therapeutics Announces Board Member David Slack Will Succeed Erkki Ruoshlahti as President & CEO
08 juil. 2020 10h15 HE
|
Cend Therapeutics Inc.
LA JOLLA, Calif., July 08, 2020 (GLOBE NEWSWIRE) -- Cend Therapeutics, Inc. (formerly DrugCendR, Inc.), a clinical-stage biotech company, announced today changes in the senior management of the...
DrugCendR Inc. Announces the Appointment of Dr. Daniel Von Hoff as Clinical Advisor
20 août 2019 13h17 HE
|
DrugCendR Inc.
LA JOLLA, Calif., Aug. 20, 2019 (GLOBE NEWSWIRE) -- DrugCendR, Inc., a clinical-stage biotech company developing next generation therapies for the treatment of solid tumors, today announced that Dr....